Lucid Capital analyst Elemer Piros initiated coverage of Okyo Pharma (OKYO) with a Buy rating and $13 price target The company is developing a drug for neuropathic corneal pain, an indication without an approved treatment, the analyst tells investors in a research note. The firm believes an efficacious treatment for an orphan eye indication, such as Oxervate for neurotrophic keratitis, can achieve blockbuster status.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
- Okyo Pharma receives $1.9M in non-dilutive funding
- Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
- OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
- Okyo Pharma reports Phase 2 clinical trial results for urcosimod